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The completion of the human genome sequence has made possible genome-wide studies of retroviral DNA
integration. Here we report an analysis of 3,127 integration site sequences from human cells. We compared retroviral
vectors derived from human immunodeficiency virus (HIV), avian sarcoma-leukosis virus (ASLV), and murine leukemia
virus (MLV). Effects of gene activity on integration targeting were assessed by transcriptional profiling of infected cells.
Integration by HIV vectors, analyzed in two primary cell types and several cell lines, strongly favored active genes. An
analysis of the effects of tissue-specific transcription showed that it resulted in tissue-specific integration targeting by
HIV, though the effect was quantitatively modest. Chromosomal regions rich in expressed genes were favored for HIV
integration, but these regions were found to be interleaved with unfavorable regions at CpG islands. MLV vectors
showed a strong bias in favor of integration near transcription start sites, as reported previously. ASLV vectors showed
only a weak preference for active genes and no preference for transcription start regions. Thus, each of the three
retroviruses studied showed unique integration site preferences, suggesting that virus-specific binding of integration
complexes to chromatin features likely guides site selection.
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Introduction
Retroviral replication requires reverse transcription of the
viral RNA genome and integration of the resulting DNA copy
into a chromosome of the host cell. A topic of long standing
interest has been the chromosomal and nuclear features
dictating the location of integration target sites (reviewed in
Cofﬁn et al. 1997; Bushman 2001). Integration site selection
has also gained increased interest because of its importance
for human gene therapy. Retroviral vectors have been used
extensively to deliver therapeutic genes carried in retroviral
backbones. However, retroviral integration can take place at
many locations in the genome, on occasion resulting in
insertional activation of oncogenes (reviewed in Cofﬁn et al.
1997; Bushman 2001). Recently, two patients undergoing gene
therapy for X-linked severe combined immunodeﬁciency
developed leukemia-like illnesses associated with integration
of a therapeutic retroviral vector in or near the LMO2 proto-
oncogene (Check 2002; Hacein-Bey-Abina et al. 2003). Inser-
tional activation of oncogenes by retroviral vectors has also
been detected in animal models (Li et al. 2002).
With the availability of the complete human genome
sequence, large-scale sequence-based surveys of integration
sites have become possible (Schroder et al. 2002; Laufs et al.
2003; Wu et al. 2003). Schroder et al. (2002) investigated
targeting of human immunodeﬁciency virus (HIV) and HIV-
based vectors in a human lymphoid cell line (SupT1) and
found that genes were favored integration targets. Global
analysis of transcription in SupT1 cells showed that active
genes were favored for integration, particularly those that
were active after infection with the HIV-based vector. Wu et
al. (2003) examined targeting of murine leukemia virus (MLV)
in human HeLa cells and found that MLV does not strongly
favor integration in transcription units, but rather favors
integration near sequences encoding mRNA 59 ends. Here we
contrast integration targeting by three retroviruses, avian
sarcoma-leukosis virus (ASLV), HIV, and MLV, taking
advantage of 1,462 new integration site sequences and
matched transcriptional proﬁling data. We ﬁnd that ASLV
does not favor integration near transcription start sites, nor
does it strongly favor active genes. For HIV, we ﬁnd that
active genes are favored for integration in two primary cell
types, extending ﬁndings from previous studies of trans-
formed cell lines. Cell-type-speciﬁc transcription was found
to result in cell-type-speciﬁc biases in integration site
placement. We also reanalyzed the MLV data from Burgess
and coworkers (Wu et al. 2003) in parallel, conﬁrming that
MLV integration is favored near transcription start sites.
Thus it appears that each retrovirus studied to date has a
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Open access, freely available online PLoS BIOLOGYunique pattern of integration site selection within the human
genome, suggesting that there may be local recognition of
chromosomal features unique to each virus.
Results
Integration Site Datasets Used in this Study
The origins of the 3,127 integration sites studied are
summarized in Table 1. All were generated by acute infection
of cells with retroviruses or with viruses generated from
retroviral vectors. To isolate integration sites, DNA from
infected cells was isolated, cleaved with restriction enzymes,
then ligated to DNA linkers. Integration sites were ampliﬁed
using one primer that bound to the viral DNA end and
another that bound the linker, then ampliﬁcation products
were cloned and sequenced (Schroder et al. 2002; Wu et al.
2003). Integration sites were mapped on the draft human
genome sequence (Figure 1) and local features at integration
sites quantiﬁed.
Three integration site datasets were newly determined in
this study. Integration by an ASLV vector was analyzed in
293T-TVA cells, which are human 293T cells engineered to
express the subgroup A avian retrovirus receptor. Integration
by an HIV-based vector was characterized in two types of
primary human cells, peripheral blood mononuclear cells
(PBMCs) and IMR90 lung ﬁbroblasts. Several previously
described datasets were also subjected to further analysis in
parallel—HIV integration sites in three transformed cell lines
(SupT1 [Schroder et al. 2002], H9, and HeLa [Wu et al. 2003])
and MLV integration sites in HeLa cells (Wu et al. 2003).
The use of restriction enzymes to cleave cellular DNA
during the cloning of integration sites could potentially
introduce a bias in favor of isolating integration events closer
to restriction sites. Previous work suggested that integration
site surveys were not strongly biased. In one study, an
experimental control based on integration in vitro indicated
that the cloning and analytical methods used did not
detectably bias the conclusions (Schroder et al. 2002). In
addition, HIV integration sites cloned by different methods
showed a similar preference for active genes (Carteau et al.
1998; Schroder et al. 2002; Wu et al. 2003), including sites
isolated using several different restriction enzymes to cleave
cellular DNA prior to linker ligation, and isolation using
inverse PCR instead of ligation-mediated PCR.
In this study we have added a computational method to
address possible biased isolation. Each integration site was
paired with ten sites in the human genome randomly selected
in silico that were constrained to be the same distance from a
restriction site of the type used for cloning as the
experimentally determined integration site. Statistical tests
were then carried out by comparing each experimentally
determined integration site to the ten matched random
control sites. In this way any bias due to the placement of
restriction sites in the human genome was accounted for in
the statistical analysis. All the collections of integration sites
were analyzed in this manner, including data previously
published in (Schroder et al. 2002; Wu et al. 2003). However,
direct analysis of the distribution of integration sites without
this correction yielded generally similar conclusions, suggest-
ing that restriction site placement did not introduce a strong
bias. A detailed description of the statistical analysis is
presented in Protocol S1 (p. 2).
Integration in Transcription Units
For HIV the frequency of integration in transcription units
ranged from 75% to 80%, while the frequency for MLV was
61%andforASLVwas57%.Forcomparison,about45%ofthe
human genome is composed of transcription units (using the
Acembly gene deﬁnition). Analysis using the different catalogs
of human genes suggests that somewhat different fractions of
the human genome are transcribed, and new information
indicates that an unexpectedly large fraction of the human
genome may be transcribed into noncoding RNAs (Cawley et
al. 2004). However, for comparisons using any catalog of the
human genes, the rate of integration in human transcription
units determined experimentally was substantially higher than
in the matched random control sites (Protocol S1, p. 3–11).
We next assessed the placement of integration sites within
genes and intergenic regions. A previous study revealed that
integration by MLV is favored near transcription start sites,
but no such bias was seen for HIV (Wu et al. 2003). We
investigated this issue for ASLV and reanalyzed all of the
available data by comparison to the matched random control
dataset (Figure 2). For sites within genes, MLV showed a
highly signiﬁcant bias in favor of integration near tran-
scription start sites (p = 1.4 3 10
 14). No such bias was seen
for ASLV (p . 0.05). For the HIV datasets, two of the four sets
showed modest bias (HIV/PBMC, p=0.0007; HIV/H9 and
HeLa combined, p=0.027). For HIV, the observed statistical
signiﬁcance was sensitive to the details of analytical approach
used and is of questionable biological importance. Thus,
ASLV and HIV do not strongly favor integration at tran-
scription start sites as was seen with MLV.
Table 1. Integration Site Datasets Used in This Study
Virus or Vector Cell Type Number of
Integration Sites
Percent Genes:
Targeted/Matched Control
Source
HIV vector PBMC 528 1.84 (p=1.8 3 10
 48) This report
HIV vector IMR-90 465 1.6 (p=6.25 3 10
 26) This report
HIV vector SupT1 436 1.72 (p=6.21 3 10
 33) Schroder et al. 2002
HIV/HIV vector H9/HeLa 407 1.66 (p=3.09 3 10
 27) Wu et al. 2003
ASLV vector 293-TVA 469 1.23 (p=3.11 3 10
 5) This report
MLV vector HeLa 822 1.33 (p=4.80 3 10
 15) Wu et al. 2003
DOI: 10.1371/journal.pbio.0020234.t001
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Retroviral Integration Targeting in HumansEffects of Transcriptional Activity on Integration
Transcriptional proﬁling analysis was carried out in some
of the cell types studied, allowing the inﬂuence of transcrip-
tional activity on integration site selection to be assessed.
Transcriptional proﬁling was carried out on infected cells so
that the data reﬂected the known inﬂuence of infection on
cellular gene activity (Corbeil et al. 2001; Schroder et al. 2002;
Mitchell et al. 2003; van ’t Wout et al. 2003). Prior to isolating
RNA for microarray analysis, the SupT1, PBMC, and IMR90
cells were each infected with the HIV-based vector used for
HIV integration site isolation. The 293T-TVA cells were
infected with the RCAS ASLV vector prior to RNA isolation.
RNA samples were harvested 24–48 h after infection. For
analysis of MLV and HIV integration sites in HeLa cells,
published transcriptional proﬁling data from uninfected cells
were used (Tian et al. 2002).
The median expression level (average difference value) of
genes hosting integration events was consistently higher than
the median of all genes assayed on the microarrays. The ratios
(targeted genes/all genes assayed) for HIV ranged from 1.6 to
3.0, indicating that integration targeting in human primary
cells (PBMC and IMR90) favored active genes, as shown
previously for transformed cell lines (Schroder et al. 2002; Wu
et al. 2003). For MLV and ASLV the ratios were each 1.3,
lower than for HIV but still greater than the chip average.
The analysis shown in Figure 3 reveals that the association of
Figure 1. Relationship between Integration Sites and Transcriptional Intensity in the Human Genome
The human chromosomes are shown numbered. HIV integration sites from all datasets in Table 1 are shown as blue ‘‘lollipops’’; MLV integration
sites are shown in lavender; and ASLV integration sites are shown in green. Transcriptional activity is shown by the red shading on each of the
chromosomes (derived from quantiﬁcation of nonnormalized EST libraries, see text). Centromeres, which are mostly unsequenced, are shown as
grey rectangles.
DOI: 10.1371/journal.pbio.0020234.g001
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Retroviral Integration Targeting in Humansintegration sites with gene activity was statistically signiﬁcant
for all the HIV datasets. For MLV and ASLV, there was a weak
tendency for integration to favor active genes, but the trend
did not achieve statistical signiﬁcance.
All three HIV datasets showed reduced integration in the
most highly expressed category of genes analyzed, suggesting
that although transcription favors integration, very high level
transcription may actually be less favorable (Figure 3). A
fourth dataset monitoring infection by an HIV-based vector
in a T-cell line also showed this trend (M. Lewinski, P. S., J. R.
E., and F. D. B., unpublished data). Possibly this ﬁnding is
related to that of a previous study of integration by ALV in a
model gene that also suggested that high level transcription
may disfavor integration (Weidhaas et al. 2000).
Tissue-Specific Transcription Results in Tissue-Specific
Biases in HIV Integration Site Selection
We next investigated the effects of cell-type-speciﬁc tran-
scription on integration site selection. For this analysis we
used only the three HIV integration site datasets for which we
had transcriptional proﬁling data from infected cells (i. e.,
SupT1, PBMC, and IMR90), to allow us to control for the
effects of infection on transcription. Pairwise comparisons of
themicroarraydatasetsforthethreecelltypesshowedthatthe
correlation coefﬁcients ranged only from 0.64 to 0.79,
indicating that transcriptional activity indeed differed among
cell types. We reasoned that since active transcription favors
integration, then the genes targeted by integration should on
average be more highly expressed in the cell type that hosted
theintegrationeventthanineitheroftheothertwo.Statistical
analysis (Figure 4) showed that transcription of targeted genes
was higher on average in the cell type hosting the integration
event than in either of the other two tested (all comparisons
attain p , 0.05 using the Chi-square test for linear trend in
proportions). We note, however, that the differences were
quantitatively modest, perhaps because much of the cellular
program of gene activity is shared among many cell types
(Caron et al. 2001; Mungall et al. 2003; Versteeg et al. 2003).
Figure 2. Integration Intensity in Genes and Intergenic Regions
Genes or intergenic regions were normalized to a common length and then divided into ten intervals to allow comparison. The number of
integration sites in each interval was divided by the number of matched random control sites and the value plotted. A value of one indicates no
difference between the experimental sites and the random controls. Viruses and cell types studied are as marked above each graph. The
direction of transcription within each gene is from left to right. Note that our normalization method de-emphasizes favored MLV integration
events just upstream of gene 59 ends (outside transcription units), as reported by Wu et al. (2003). We carried out an analysis specially designed to
identify this effect and conﬁrmed that the regions just upstream of gene 59 ends are favored for MLV integration when reanalyzed with the
matched random control data (unpublished data).
DOI: 10.1371/journal.pbio.0020234.g002
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Retroviral Integration Targeting in HumansIntegration Site Selection and Transcriptional Domains
We next analyzed factors inﬂuencing the placement of
integration sites at the chromosomal level, taking into account
both gene density and expression (see Figure 1). Transcrip-
tional activity was quantiﬁed by counting the EST sequence
copies for each gene present in a collection of nonnormalized
EST libraries (Mungall et al. 2003). EST sequences from many
tissues were used to build up the map of transcriptional
activity, thus focusing the analysis on transcriptional patterns
common to many cell types (Caron et al. 2001; Mungall et al.
2003; Versteeg et al. 2003). A detailed comparison of the
relationship between EST frequency and integration fre-
quency of HIV, MLV, and ASLV is shown for Chromosome 11
in Figure 5. Integration frequency for HIV closely parallels the
transcriptional intensity deduced from EST counts. Fewer
sites are available for analyzing MLV and ASLV, but MLV may
show a related trend, while it is unclear whether ASLV does so
or not. Similar analysis of the other human chromosomes
yields similar conclusions (unpublished data).
Statistical analysis was carried out comparing integration
frequencies to (1) gene density or (2) transcriptional intensity,
as measured by the EST counts. All analyses incorporated a
comparison to the matched random control set of integration
sites. Each type of vector showed a signiﬁcant positive
correlation with gene density (HIV, p=1.8 3 10
 12 to 3.2 3
10
 38, depending on the dataset; MLV, p=2.4310
 22; ASLV,
p=3.2 3 10
 9) and a stronger association with transcrip-
tional intensity (HIV, p=3.8310
 19 to 9.7310
 46; MLV, p=
5.1310
 35; ASLV, p=1.7310
 11). Overall, ASLV showed the
weakest association with gene density and transcriptional
intensity.
Thus, the analysis of transcriptional activity in the context
of chromosomal location revealed signiﬁcant effects of
transcription on MLV and ASLV integration. This is in
contrast to the study based on transcriptional proﬁling alone,
in which the effect was not statistically signiﬁcant—however,
a similar trend was evident and the general conclusions
similar (see Figure 3). It appears that adding information on
chromosomal position to the gene expression data allowed
quantitatively modest effects to reach statistical signiﬁcance.
Substructures within Chromosomal Regions Favorable for
Integration
Two lines of evidence indicated that the chromosomal
regions favorable for integration can be subdivided into
favorable and unfavorable segments. In the ﬁrst study, a
computational analysis was carried out to determine the
length of the chromosomal segments yielding the best ﬁt
between transcriptional intensity and integration intensity.
The sizes of the chromosomal regions analyzed were varied
systematically from 25 kb to 32,000 kb, and the statistical
signiﬁcance determined for the correlations. This analysis
revealed that the segment length yielding the best correlation
was comparatively short, around 100–250 kb, the length of
one or a few human genes. These conclusions held for HIV,
ASLV, and MLV (Protocol S1, p. 16–65).
Figure 3. Influence of Gene Activity on Integration Frequency
Expression levels were assayed using Affymetrix HU-95Av2 or HU-
133A microarrays and scored by the average difference value as
deﬁned in the Affymetrix Microarray Suite 4.1 software package. All
the genes assayed by the chip were divided into eight ‘‘bins’’
according to their relative level of expression (the leftmost bin in
each panel is lowest expression levels and the rightmost the highest).
Genes that hosted integration events were then distributed into the
same bins, summed, and expressed as a percent of the total. The y-
axis indicates the percent of all genes in the indicated bin. P values
were determined using the Chi-square test for trends by comparison
to a null hypothesis of no bias due to expression level. All average
difference values were ranked prior to analysis, and the analysis was
carried out on the ranked data. This was done to avoid possible
complications due to differential normalization or other data
processing differences arising during work up of the microarrays.
DOI: 10.1371/journal.pbio.0020234.g003
PLoS Biology | www.plosbiology.org August 2004 | Volume 2 | Issue 8 | e234 1131
Retroviral Integration Targeting in HumansAn analysis of integration frequency near CpG islands also
indicated substructure within regions favorable for integra-
tion. CpG islands are chromosomal regions enriched in the
rare CpG dinucleotide. These regions commonly correspond
to gene regulatory regions containing clustered transcription
factor binding sites—consequently, CpG islands are more
frequent in gene-rich regions. Previously Wu et al. (2003)
reported that CpG islands were positively associated with
MLV integration sites but that for HIV integration sites there
was no inﬂuence. An analysis of the effects of proximity to
CpG islands on integration frequency incorporating the
matched random control dataset is shown in Figure 6. The
relative integration frequency near CpG islands was found to
be much higher than expected by chance for MLV, as
reported previously, and slightly higher than expected by
chance for ASLV. For HIV, the region surrounding CpG
islands was actually disfavored, and this was statistically
signiﬁcant in three out of four datasets. Thus for HIV,
broadly favorable gene-dense chromosomal regions actually
contain a mixture of favorable clusters of active genes and
unfavorable CpG islands. For MLV, in contrast, CpG islands
are quite favorable.
High gene density in the human chromosomes is known to
correlate with several other features, including high levels of
gene expression, high densities of CpG islands, the occur-
rence of Giemsa-light chromosomal bands, and high G/C
content (Caron et al. 2001; Lander et al. 2001; Venter et al.
2001; Mungall et al. 2003; Versteeg et al. 2003). The effects of
chromosomal banding pattern and G/C content were ana-
lyzed statistically and found to favor integration, as expected
from the correlation with other favorable features (Protocol
S2).
A Quantitative Model for Integration Intensity
A statistical model was constructed to examine the relative
contributionstointegrationintensityof(1)genedensity,(2)gene
activity, (3) proximity to CpG islands, (4) G/C content, and (5)
locationwithingenes(ProtocolS2,p.13–15).Inclusionofeachof
theseparametersimprovedtheﬁtofthemodeltotheobserved
experimentaldatasets,butthequantitativecontributionofeach
parameter varied among the different retrovirus types. The
effectsofbeinginageneoraregionwithmanyexpressedgenes
weremostimportantforHIVandASLV.ForMLV,thedistance
from the transcription starts i t ew a st h em o s ti m p o r t a n t
parameter. ASLV differed signiﬁcantly from each of the other
datasets (p , 0.0001), and the model based on the above
parameters predicted the placement of ASLV integration sites
least well. Thus ASLV is least responsive to the effects of the
parameters so far known to affect integration site selection in
human cells.
Figure 5. Comparison of Transcriptional Intensity to Integration Intensity
on Human Chromosome 11
All data were quantiﬁed in 2-Mb intervals. The top line shows
summed EST data documenting the ‘‘transcriptional intensity’’ for
each chromosomal interval (data from Mungall and al. [2003]). The
bottom three lines show the summed frequency of integration site
sequences in each interval. The numbers of ESTs (top) or integration
sites (bottom three) are shown on the y-axis.
DOI: 10.1371/journal.pbio.0020234.g005
Figure 4. Effects of Tissue-Specific Transcription on Integration Site Selection in Different Cell Types
Genes hosting integration events by the HIV vector were analyzed for their expression levels in transcriptional proﬁling data from IMR90,
PBMC, and SupT1 cells. For each gene hosting an integration event, the expression values from the three cell types were then ranked lowest
(red), medium (orange), and highest (yellow). The values were summed and displayed separately for each set of integration sites: (A) IMR90 sites,
(B) PBMC sites, and (C) SupT1 sites. In each case there was a signiﬁcant trend for the cell type hosting the integration events to show the highest
expression values relative to the other two (p , 0.05 for all comparisons).
DOI: 10.1371/journal.pbio.0020234.g004
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Retroviral Integration Targeting in HumansIntegration Frequency in the Individual Human
Chromosomes
Figure 7 presents the frequency of integration in each of
the different human chromosomes for HIV, MLV, and ASLV.
For HIV, each of the datasets is shown separately. A statistical
analysis was carried out comparing the observed frequency of
integration in each chromosome to that expected from the
matched random control (Protocol S1, p. 3). As can be seen
from the ﬁgure, the frequencies were quite different among
the different chromosomes. For example, the gene-rich
Chromosome 19 showed more integration than expected by
chance, while the gene-poor Chromosome 18 showed less
integration. The differences in integration frequencies
among chromosomes are in part a function of gene density.
However, for unknown reasons, the datasets also differed
signiﬁcantly from each other (p , 2.22 3 10
 16). Evidently
there are factors—so far unknown—affecting integration
targeting that operate at the level of whole chromosomes
(a conclusion also reached by Laufs et al. [2003]).
Discussion
We report that ASLV, MLV, and HIV have quite different
preferences for integration sites in the human chromosomes.
HIV strongly favors active genes in primary cells as well as in
transformed cell lines. MLV favors integration near tran-
scription start regions and favors active genes only weakly.
ASLV shows the weakest bias toward integration in active
genes and no favoring of integration near transcription start
sites. We expect that these same patterns will be seen for MLV
and ASLV integration in different human cell types, because
all four HIV datasets yielded similar results, though more
Figure 6. The Effects of Proximity to CpG Islands Differs for HIV, MLV, and ASLV Integration
The viral vectors and cell types studied are indicated by color. A value of one indicates no bias, less than one indicates disfavored integration,
and more than one indicates favored integration. The x-axis (from plus or minus 1 kb to 50 kb) indicates distance from the edge of a CpG island
in either direction along the genome. The statistical analysis speciﬁcally removed the favorable effects of being in a gene and being in a region
containing expressed genes to highlight the effects of CpG islands alone. When effects of gene density and activity are left in, HIV integration
goes from disfavored at short distances (less than 1 kb) to favored at longer distances (more than 10 kb). This is because at longer distances the
association with genes is signiﬁcant—many CpG islands are within 10 kb of a gene, and genes are favored targets for HIV integration. To carry
out this analysis, the numbers of experimentally determined and matched control sites were ﬁtted according to whether they were near a CpG
island, whether they were in genes, and the level of the expression density variable. Each variable contributes a ‘‘multiplier’’ for the ratio of the
number of experimental to control sites. The multiplier for ‘‘near CpG island’’ is shown (see Protocol S2, p. 9–12).
DOI: 10.1371/journal.pbio.0020234.g006
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Retroviral Integration Targeting in Humansdata on additional cell and tissue types will be helpful to
further evaluate the generality.
One of the earliest models for chromosomal inﬂuences on
integration targeting proposed that condensed chromatin in
inactive regions disfavored integration, thereby concentrat-
ing integration in more open active chromatin (Panet and
Cedar 1977; Vijaya et al. 1986; Rohdewohld et al. 1987).
Integration by HIV, ASLV, and MLV all showed at least a
weak bias in favor of integration in active genes, consistent
with the idea that open chromatin at active genes favors
integration. Also consistent with this idea, heterochromatic
regions at human centromeres and telomeres were found to
disfavor integration.
However, it seems unlikely that relative accessibility is the
only feature directing integration site selection, because HIV,
ASLV, and MLV each show such distinctive target sequence
preferences. Studies of the Ty retrotransposons of yeast, close
relatives of retroviruses, have revealed that interactions with
bound chromosomal proteins can tether the Ty integration
machinery to chromosomes and thereby direct integration to
nearby sites (Boeke and Devine 1998; Bushman 2003;
Sandmeyer 2003; Zhu et al. 2003). Such a model may explain
integration targeting by retroviruses as well (Bushman 2003).
HIV integration complexes might bind to factors enriched at
active genes, while MLV complexes could bind to factors
bound near transcription start sites. In support of this idea, in
vitro studies have established that retroviral integrase
enzymes fused to sequence-speciﬁc DNA-binding domains
Figure 7. Frequency of Integration in Human Chromosomes
Human chromosome numbers are indicated at the bottom of the ﬁgure. The number of integration events detected in each chromosome was
divided by the number expected from the matched random control. The line at one indicates the bar height expected if the observed number of
integration events matched the expected number. Higher bars indicate favored integration, lower bars, disfavored integration. Most of the cell
types studied were from human females; too little data were available for the Y chromosome for meaningful analysis.
DOI: 10.1371/journal.pbio.0020234.g007
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Retroviral Integration Targeting in Humanscan direct integration preferentially to local regions when
tethered at speciﬁc DNA sites (Bushman 1994; Goulaouic and
Chow 1996; Katz et al. 1996).
The analysis of chromosomal regions favored for integra-
tion also suggested a role for locally bound proteins.
Chromosomal regions enriched in active genes were generally
favorable, but further analysis revealed interleaved favorable
and unfavorable regions. Statistical tests indicated that
favorable regions were typically short (100–250 kb), and for
HIV these were interspersed with unfavorable regions near
CpG islands. CpG islands are thought to be regulatory regions
that bind distinctive sets of transcription factors. Thus, a
simple model to explain targeting is that a distinctive set of
sequence-speciﬁc DNA-binding proteins bound at or near
CpG islands disfavor HIV integration, while proteins bound
in active transcription units are favorable. For MLV, the
proteins bound at CpG islands instead favor integration.
For ASLV, it is possible that the viral integration
machinery does not interact with factors bound in or near
genes, explaining the more random distribution of integra-
tion sites in the genome. Such a pattern might have evolved
to minimize disruption to the host cell chromosomes due to
integration. Another possibility, however, is that ASLV does
have stricter target site preferences during normal integra-
tion in chicken cells, but the targeting system does not
function properly in the human cells studied here. According
to this idea, putative chicken chromosomal proteins normally
bind ASLV integration complexes and direct integration, but
the homologous human proteins may be too different to
interact properly. It should be possible to investigate this
possibility by characterizing ASLV integration in chicken
cells, now that the draft chicken genome sequence is
completed (Ren et al. 2003).
One consequence of the above ﬁndings is that integration
will differ from tissue to tissue as a consequence of cell-type-
speciﬁc transcription. To assess effects of tissue-speciﬁc
transcription, we analyzed HIV integration in three different
cell types (SupT1, PBMC, and IMR90). Transcriptional
proﬁling data showed that transcription was signiﬁcantly
different among the three. This allowed an analysis of
integration targeting, which showed that highly expressed
genes particular to each tissue were favored for integration in
that tissue. However, the magnitude of the tissue-speciﬁc
biases on integration were modest, probably because most of
the cellular transcriptional program appears to be common
among cell types (Caron et al. 2001; Mungall et al. 2003;
Versteeg et al. 2003).
Additional mechanisms could also contribute to targeting.
For example, we and others have detected statistically
signiﬁcant biases in integration frequency in whole chromo-
somes that do not appear to be fully explained by gene
density or gene activity (Schroder et al. 2002; Laufs et al. 2003;
data reported here). Perhaps the intranuclear position of
chromosomes may have an inﬂuence, since this has been
proposed to be relatively ﬁxed for cells of speciﬁc types but
may differ among cell types (Boyle et al. 2001; Chubb and
Bickmore 2003).
Our data indicate that ASLV has integration site prefer-
ences that may make it attractive as a vector for human gene
therapy. MLV-based vectors have the unfavorable preference
for integration near transcription start sites (Wu et al. 2003).
The adverse events arising during X-linked severe combined
immunodeﬁciency gene therapy involved integration of an
MLV vector near the transcription start region of the LMO2
proto-oncogene. HIV-based vectors strongly favor integra-
tion in active genes, which is also likely to be disruptive to the
host cell genome (Schroder et al. 2002; Wu et al. 2003). ASLV,
in contrast, shows only weak favoring of integration in active
genes, and no favoring of integration near transcription start
sites. A quantitative model based on gene density, expression,
and proximity to transcription start regions ﬁt the ASLV data
least well, indicating that ASLV has the weakest bias toward
integration in these unfavorable locations. ASLV vectors are
known to infect a variety of human cell types (e. g., Valsesia-
Wittmann et al. 1994; Federspiel and Hughes 1997; Hat-
ziioannou and Goff 2001; Katz et al. 2002) and can transduce
nondividing cells (Hatziioannou and Goff 2001; Katz et al.
2002), adding to their possible utility. More generally, this
study, together with previous work (Schroder et al. 2002; Wu
et al. 2003), indicates that the selection of different retroviral
integration systems can modulate the selection of integration
target sites, and this may potentially be exploited for safer
gene therapy.
Materials and Methods
Oligonucleotides used in this study. Each oligonucleotide is
described by its name, sequence (written 59 to 39), and use, in that
order. HincII adaptor, GTAATACGACTCACTATAGGG-
CACGCGTGGTCGACGGCCCGGGCTGC, adapter for use with
DNA cleaved by 6-cutter restriction enzymes, top strand; mNheIAv-
rIISpeII adaptor, P-CTAGGCAGCCCG-NH2, adapter for 6-cutter
restriction enzymes, bottom strand; ASB-9, GACTCACTATAGGG-
CACGCGT, adapter primer for PCR for I/SupT1, PBMC, and IMR-90;
SB-76, GAGGGATCTCTAGTTACCAGAGTCACA, HIV primer for
PCR for I/SupT1; ASB-19, GAGATTTTCCACACTGAC-
TAAAAGGGTC, HIV primer for PCR for I/PBMC and IMR-90;
ASB-16, GTCGACGGCCCGGGCTGCCTA, adapter primer for nested
PCR for I/SupT1, PBMC, and IMR-90; ASB-1, AGCCAGAGAGCTCC-
CAGGCTCAGATC, HIV primer for nested PCR for I/SupT1; ASB-20,
CTGAGGGATCTCTAGTTACCAGAGTCA, HIV primer for nested
PCR forPBMC and IMR-90; MseI linker þ, GTAATACGACTCACTA-
TAGGGCTCCGCTTAAGGGAC, MseI linker, top strand; MseI linker
 , P-TAGTCCCTTAAGCGGAG-NH2, MseI linker, bottom strand;
MseI linker primer, GTAATACGACTCACTATAGGGC, MseI linker
primer for ﬁrst round of PCR; MseI linker nested primer,
AGGGCTCCGCTTAAGGGAC, MseI linker nested primer for second
round of PCR; BB389, GATGGCCGGACCGTTGATTC, inner ASLV
LTR primer for second round of ‘‘nested’’ PCR; BB390, CGATA-
CAATAAACGCCATTTGACCATTC, outer ASLV LTR primer for
ﬁrst round of PCR.
Preparation of the ASLV- and HIV-based vectors. To produce HIV
vector particles, 293T cells were cotransfected with three plasmids:
one encoding the HIV vector segment (p156RRLsin-
PPTCMVGFPWPRE) (Follenzi et al. 2000), the second, the packaging
construct (pCMVdeltaR9) (Naldini et al. 1996), and the third, the
gene for VSV-G (pMD.G) (Naldini et al. 1996). Forty-eight hours
after transfection, supernatants were collected, centrifuged to pellet
cellular debris, then ﬁltered through 0.45-lm ﬁlters. Viral particles
were further puriﬁed by centrifugation at 23,000g and resuspended
in 1/17 volume of fresh medium. ASLV particles were generated by
transfecting the DF-1 chicken embryonic ﬁbroblast cell line (ATCC
CRL-12203) with the plasmid RCASBP(A)GFP (from Steve Hughes,
National Cancer Institute, Frederick, Maryland). Supernatant was
removed from the cells 4 d post transfection (when cells were
nearly 100% GFP positive) and ﬁltered though a 0.45-lm syringe
ﬁlter.
Infections. PBMCs were separated from human blood using a ﬁcoll
gradient (Amersham Biosciences, Little Chalfont, United Kingdom). 1
3 10
7 PHA, IL-2 prestimulated PBMCs, or IMR-90 cells (passage #36)
at 30%–50% conﬂuency (1–2310
6 cells) were infected with the HIV-
based vector at an moi of 10 (60 ng p24 per 5310
5 cells). The vector
was added to the cells with DEAE-dextran at a ﬁnal concentration of
5 lg/ml. Forty-eight hours after infection, the cells were pelleted. For
RNA isolation, cells were resuspended in 250 ll of PBS and 750 llo f
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infection, cells were analyzed by ﬂow cytometry. For ASLV, super-
natant containing RCASBP(A)GFP particles was added to 293T-TVA
cells (293T 0.8 cells; a gift from John Young, Salk Institute) at 30%–
50% conﬂuency. Forty-eight hours post infection, green ﬂuorescence
was seen in approximately 30% of the cells, as determined by
examination of the cultures with a ﬂuorescence microscope. DNA was
harvested at this point (DNeasy, Qiagen, Valencia, California, United
States). RNA from infected cells was also isolated at 48 h post
infection (TRIzol) and stored at  80 8C until used for transcriptional
proﬁling analysis. RNA was isolated from infected cell cultures, and
samples from each were used for hybridization on one Affymetrix
(Santa Clara, California, United States) microarray.
Integration site determination. HIV integration sites were cloned
by ligation-mediated PCR essentially as described in Schroder et al.
(2002). ASLV integration site determination using ligation-mediated
PCR was carried out essentially as described in Wu et al. (2003).
Oligonucleotides used are summarized above. All novel integration
site sequences are deposited at the National Center for Biotechnol-
ogy Information (NCBI) (accession numbers CL528318–CL529767).
Integration sites from earlier studies were reanalyzed on the
November 2002 freeze of the human genome sequence (using the
University of California at Santa Cruz browser), and a few were
excluded because they did not ﬁnd matches of sufﬁciently high
quality on the new draft sequence, accounting for slightly different
numbers than in previous reports. This study used primarily the
Acembly and Ensemble human gene catalogs; similar results were
generally obtained when the Unigene, RefGene, or GeneScan catalogs
of the human genes were used (Protocol S1, p. 3–10).
Transcriptional proﬁling analysis. Transcriptional proﬁling was
carried out using Affymetrix microarrays as described in Schroder et
al. (2002). Gene expression levels (average difference values) were
analyzed using Affymetrix Microarray Suite 4.1 software. All novel
transcriptional proﬁling datasets reported here are deposited at
NCBI (GEO dataset numbers GSE1407, GSE1408, GSE1409, and
GSE1410). For the analysis in Figure 3, a complication was introduced
by the fact that the HU95A chips used have multiple probe sets for
some genes but not others. In our analysis all probe sets were
accepted and analyzed in these cases.
Statistical analysis. A detailed description of the statistical methods
used is presented in Protocols S1 and S2.
Supporting Information
Protocol S1. Association of Genomic Features with Integration—
Part 1
Found at DOI: 10.1371/journal.pbio.0020234.sd001 (322 KB PDF).
Protocol S2. Association of Genomic Features with Integration—
Part 2
Found at DOI: 10.1371/journal.pbio.0020234.sd002 (128 KB PDF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/) accession numbers for
the novel integration site sequences discussed in this paper are
CL528318–CL529767. The GenBank GEO dataset numbers for the
novel transcriptional proﬁling datasets reported here are GSE1407,
GSE1408, GSE1409, and GSE1410.
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